HJF Medical Research International, Inc., Mbeya, Tanzania.
U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
AIDS Res Ther. 2020 Nov 12;17(1):66. doi: 10.1186/s12981-020-00323-x.
With increased use of antiretroviral therapy (ART), HIV mortality rates are declining and people living with HIV (PLWH) are surviving longer. We characterized CD4 recovery and viral suppression among adults aged < 50 and ≥ 50 years living with HIV who initiated ART in the African Cohort Study (AFRICOS).
Beginning in January 2013, PLWH at twelve clinics in Kenya, Uganda, Tanzania and Nigeria underwent medical history review, CD4 and viral load testing as part of the ongoing African Cohort Study (AFRICOS). ART-naïve PLWH who initiated ART within 30 days of enrollment and had at least one year of follow-up were included in these analyses. To compare ART response in participants < 50 years and ≥ 50 years old, changes in CD4 count and viral load suppression after ART initiation were examined at different time points using linear and binomial regression with generalized estimating equations. Variables for time since ART initiation and the interaction between age group and time on ART were included in the model to evaluate longitudinal changes in CD4 recovery and viral suppression by age.
Between January 2013 and September 2019, 2918 PLHV were enrolled in the cohort. Of these, 443 were ART naïve and initiated on ART within 30 days of enrollment, with 90% (n = 399) aged < 50 years old at ART initiation. At ART initiation, participants aged 50 and older had a higher median CD4 count compared to participants younger than 50 years of age although it did not reach statistical significance (306 cells/mm, IQR:130-547 vs. 277cells/mm, IQR: 132-437). In adjusted models examining CD4 recovery and viral suppression there were no significant differences by age group over time. By the end of follow-up viral suppression was high among both groups of adults (96% of adults ≥ 50 years old and 92% of adults < 50 years old).
This study found no difference in long-term CD4 recovery or viral suppression by age at ART initiation. We found that particularly among younger adults participants had lower median CD4 counts at ART initiation, suggesting the importance of identifying and putting this population on treatment earlier in the disease course.
随着抗逆转录病毒疗法(ART)的广泛应用,HIV 死亡率正在下降,HIV 感染者(PLWH)的存活时间也在延长。我们描述了在非洲队列研究(AFRICOS)中,年龄<50 岁和≥50 岁的开始接受 ART 的 HIV 感染者的 CD4 恢复和病毒抑制情况。
从 2013 年 1 月开始,肯尼亚、乌干达、坦桑尼亚和尼日利亚的 12 个诊所的 PLWH 接受了病史回顾、CD4 和病毒载量检测,这是正在进行的非洲队列研究(AFRICOS)的一部分。在这些分析中,纳入了在入组后 30 天内开始 ART 且至少有 1 年随访的 ART 初治 PLWH。为了比较<50 岁和≥50 岁的参与者的 ART 反应,使用线性和二项回归与广义估计方程,在不同时间点检查 CD4 计数和病毒载量抑制的变化。在模型中纳入了自 ART 开始的时间和年龄组与 ART 上的时间之间的交互作用变量,以评估按年龄划分的 CD4 恢复和病毒抑制的纵向变化。
2013 年 1 月至 2019 年 9 月,该队列共纳入了 2918 名 PLHV。其中,443 名是 ART 初治,在入组后 30 天内开始接受 ART,90%(n=399)在 ART 开始时年龄<50 岁。在开始 ART 时,50 岁及以上的参与者的 CD4 计数中位数高于 50 岁以下的参与者,尽管差异无统计学意义(306 个细胞/mm,IQR:130-547 与 277 个细胞/mm,IQR:132-437)。在调整后的模型中,按年龄组观察到 CD4 恢复和病毒抑制没有随时间的显著差异。在随访结束时,两组成年人的病毒抑制率都很高(96%的 50 岁及以上成年人和 92%的<50 岁成年人)。
本研究发现,ART 开始时的年龄与长期 CD4 恢复或病毒抑制无关。我们发现,特别是在年轻成年人中,参与者在开始 ART 时的 CD4 计数中位数较低,这表明在疾病过程中更早识别并将这部分人群纳入治疗的重要性。